OSR (NASDAQ:OSRH) versus Anavex Life Sciences (NASDAQ:AVXL) Critical Review

OSR (NASDAQ:OSRH) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Volatility and Risk

OSR has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares OSR and Anavex Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Institutional and Insider Ownership

55.3% of OSR shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for OSR and Anavex Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
Anavex Life Sciences	1	1	3	0	2.40

Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 498.41%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than OSR.

Valuation and Earnings

This table compares OSR and Anavex Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81 million	2.37	-$27.06 million	($0.37)	-0.33
Anavex Life Sciences	N/A	N/A	-$46.38 million	($0.39)	-9.14

OSR has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Summary

OSR beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.